The Treatment of Anal Squamous Cell Carcinoma in a High HIV Prevalence Population

Danielle Brogden  
Imperial College London

Christopher Khoo  
Chelsea and Westminster Hospital NHS Foundation Trust

Christos Kontovounisios (✉️ c.kontovounisios@imperial.ac.uk)  
Imperial College London

Gianluca Pellino  
University of Campania "Luigi Vanvitelli"

Irene Chong  
Royal Marsden NHS Foundation Trust

Diana Tait  
Royal Marsden NHS Foundation Trust

Oliver Warren  
Chelsea and Westminster Hospital NHS Foundation Trust

Mark Bower  
Chelsea and Westminster Hospital NHS Foundation Trust

Paris Tekkis  
Imperial College London

Sarah Mills  
Chelsea and Westminster Hospital NHS Foundation Trust

Research Article

Keywords: Anal Squamous Cell Carcinoma, HIV, Chemoradiotherapy

DOI: https://doi.org/10.21203/rs.3.rs-143774/v1

License: ☕️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Anal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of younger male persons living with HIV (PLWH) diagnosed with ASCC in Greater London.

This is a retrospective cohort study of HIV positive and HIV negative patients diagnosed with primary ASCC between January 2000 and January 2020 in a demographic group with high prevalence rates of HIV. 176 patients were included, and clinical data was retrieved from multiple, prospective databases.

A clinical subgroup was identified in this cohort of younger HIV positive males who were more likely to have had a prior diagnosis of Anal Intraepithelial Neoplasia (AIN). Gender and HIV status had no effect on staging or disease-free survival. PLWH were more likely to develop a recurrence (p < 0.000) but had a longer time to recurrence than HIV negative patients, however this was not statistically significant (46.1 months vs. 17.5 months; p = 0.077). Patients known to have a previous diagnosis of AIN were more likely to have earlier staging and local tumour excision but there was no identifiable survival benefit in this cohort.

Five-year Disease-Free Survival was associated with tumour size and the absence of nodal or metastatic disease (p < 0.000).

Introduction

Anal Squamous Cell Carcinoma (ASCC) is considered a rare cancer, with an incidence rate that is frequently quoted as between 1–2 cases per 100000 per year worldwide [1]. Nevertheless, the incidence of ASCC is rapidly increasing; Islami et al (2017) demonstrated a percentage incidence increase of between 2.8–6.8% per year in men and 1.5–10% per year in woman in Western developed countries between 1971–2007. [2]

The known risk factors for the development of ASCC include immunosuppression, smoking, receptive anal intercourse, sexually transmitted infections, previous or current Human Papillomavirus (HPV) related dysplasia and malignancies and Human Immunodeficiency Virus (HIV).[3]

HIV is a significant risk factor in the development of ASCC, and ASCC is the third most common cancer in people living with HIV (PLWH).[4] It is likely that that the increasing incidence of ASCC related to the higher number of PLWH in developed countries where, in the era of Highly Active Antiretroviral Therapy (HAART), PLWH are able to achieve a near normal life expectancy and go on to develop long-term sequelae of HIV infection.[5] Despite improving outcomes of HIV prognosis with HAART, the use of HAART does not reduce the risk of ASCC in PLWH, [4] therefore it is likely that the incidence of ASCC in PLWH will continue to rise.
ASCC is associated with persistent oncogenic Human Papillomavirus (HPV) infections and has a known HPV related dysplastic precursor; Anal Intraepithelial Neoplasia (AIN). With a similar natural history to Cervical Intraepithelial Neoplasia (CIN), it hypothesised that like cervical cancer, ASCC could become a largely preventable cancer with HPV vaccination, ASCC screening programmes and appropriate treatment for AIN when identified.

Nevertheless, the screening for, and treatment of, AIN remains controversial in clinical guidelines.[6, 7] Although clinical guidelines identify PLWH as a high-risk group for ASCC, there is significant discrepancy in the literature regarding the progression rates of high-grade AIN to ASCC[8–11] and, unlike cervical cancer screening programmes which have a good evidence base in preventing malignancy, corresponding ASCC screening programmes have not been shown to be as effective. There is also a lack of evidence that treating AIN once it has been identified can prevent ASCC.[12]

Despite the controversy, many HIV centres provide local screening services for PLWH. In our clinical centre, a high resolution anoscopy and cytology screening programme is offered to PLWH and in particular men who have receptive anal intercourse (MSM).

Historically, the majority of ASCC diagnosed are in women in their 6th or 7th decade who are likely to have had a previous high-risk HPV infection and the published literature focuses mainly on this patient demographic.[7, 13, 14] Although, research involving the screening and treatment of AIN is centred around the newly increasing PLWH demographic, there is less clinical evidence about the outcomes of the PLWH subgroup once they are diagnosed with ASCC.

We present our experience with managing patients with ASCC over two decades between 2000 to 2020 with emphasis on whether there exists a separate subpopulation of ASCC patients with HIV within the Trust and whether this affects clinical prognosis.

**Methods**

We undertook a retrospective cohort study following the “strengthening the reporting of observational studies in epidemiology (STROBE)” statement.[15] Consecutive patients undergoing treatment for Anal Squamous Cell Carcinoma between January 2000 and January 2020 were identified from prospectively maintained clinical databases. The departments of sexual health, surgery and HIV kept separate clinical databases across two clinical sites. Data entries were linked by hospital number and date of birth and then anonymised for analysis. The study protocol was reviewed and approved by the London-Westminster Research and Ethics Committee prior to data collection.

**Inclusion Criteria**

The study included all adult patients over 18 years of age diagnosed with primary histological proven Anal Squamous Cell Carcinoma (ASCC) between January 2000 and January 2020.

**Exclusion Criteria**
Patients under 18 years of age. Anal cancers with a histopathology other than Squamous Cell Carcinoma were excluded from this analysis.

**Data Collection**

For each patient included in the study, the authors retrieved data including demographics, HIV outcomes, attendance at screening, histopathology, staging, and treatment received (Table 1) from separate clinical databases and combined it to form one data record per patient. Staging and treatment were commonly repeated across clinical databases, and any discrepancies were independently checked by two independent clinical reviewers (DRLB and CCK).

| Demographics | Age          | Sex | Co-morbidities | Performance status |
|--------------|--------------|-----|----------------|--------------------|
| HIV          | Date of Diagnosis | AIDS Diagnosis | Viral Load | CD4 count |
| Sexual Health| Hepatitis B | Hepatitis C | Attendance at screening | Previous AIN Diagnosis |
| Pathology    | Staging      | Tumour differentiation | Surgical Treatment | Previous HPV related cancers |
| Oncological Treatment | Chemotherapy | Radiotherapy | Last date of follow up | Response to treatment |

**Outcome measures**

The outcome measures were recurrence, time to recurrence and 5-year disease free survival in PLWH and HIV-negative patients.

**Statistical Analysis**

Data were analysed using SPSS Statistics software. A statistically significant p value was defined as $p < 0.05$ for this analysis. Chi squared tests and Fishers exact tests were used for categorical variables and ANOVA tests were used for comparisons between means.

**Results**

**Patient Characteristics**

176 patients were included (see Fig. 1 for STROBE flow diagram), 55 patients (31%) were female, the mean age at diagnosis was 56.5 years (median 53 years, range 31–92 years) (See Tables 2 and 3 for study demographics). 96 patients were HIV positive (55%) and 32 patients (18%) were HIV negative. 27% of patients did not have a documented HIV status on retrospective chart review, they were statistically
more likely to be female (p < 0.001, Chi Squared) and have a previous diagnosis of Genitourinary Intraepithelial Neoplasia (p = 0.011, Fisher’s Exact Test).

Of the patients with a known HIV status, 75% were PLWH in this cohort. 76% of male patients were PLWH whereas only 7% of female patients were PLWH (p < 0.001, Chi Squared). 38% of PLWH included in this cohort had previously met the criteria for AIDS during their treatment for HIV. 38% of PLWH had a concurrent diagnosis of Hepatitis B, 22% Hepatitis C and 10% had both Hepatitis B and C.

Table 2
Patient Demographics and Staging

| Demographics | Male (n = 121) | Female (n = 55) | p-value |
|--------------|---------------|----------------|---------|
| Mean age (years) | 53.2 | 62.8 | p < 0.001 |
| HIV status | Positive 92 (76%), Negative 13 (11%) Not tested 16 (13%) | Positive 4 (7%), Negative 19 (35%) Not tested 32 (58%) | p < 0.001 |
| Previous AIN | 43 (34%) | 2 (4%) | p < 0.001 |
| Previous GIN | 1 (1%) | 8 (15%) | p < 0.001 |
| Stage 1 | 47 (39%) | 15 (27%) | P = 0.191 |
| stage 2A | 17 (14%) | 10 (18%) |
| Stage 2B | 4 (3%) | 1 (2%) |
| Stage 3A | 7 (6%) | 5 (9%) |
| Stage 3B | 13 (11%) | 2 (4%) |
| Stage 3C | 19 (18%) | 13 (24%) |
| Stage 4 | 8 (7%) | 2 (4%) |

Risk factors

Age

Men presented with ASCC at an earlier age than women (53.2 years compared to 62.8 years; p < 0.001, ANOVA). PLWH were also statistically more likely to present at younger age when compared to HIV
negative patients (47.9 years compared to 64.1 years; p < 0.001, ANOVA). There was no statistical difference in age when comparing patients with and without a previous AIDS diagnosis, previous diagnosis of intraepithelial neoplasia, other predisposing skin conditions and immunosuppression. Patients with metastatic disease were statistically more likely to be older (67.5 years compared to 54.3 years; p = 0.007, ANOVA). With the exception of patients receiving Radiotherapy alone who were statistically older than patients receiving other treatment modalities (78.3 years compared to 54.5 years; p < 0.001, ANOVA) there was no statistical difference in age and choice of treatment modality between groups.

**Gender**

Men were more likely to have HIV (p < 0.001, Chi Squared), and to have had previous treatment for AIN (p < 0.001, Fisher's Exact Test). A higher proportion of male patients presented with an early cancer (Stage 1 and 2: 56% compared to 47%) but this was not statistically significant (Fig. 2). There was no difference in gender proportions when comparing treatment modalities, recurrence rates and disease-free survival.

| Table 3 | Patient Demographics by Documented HIV Status |
|---------|-----------------------------------------------|
| **Demographics** | **HIV Positive** | **HIV Negative** | **Not Tested** | **p-value** |
| Mean age (Years) | 47.9 | 64.1 | 66.0 | P < 0.001 |
| | Standard Deviation = 8.6 Range 31–73 years | Standard Deviation = 14.2 Range 32–90 years | Standard Deviation = 12.5 Range 38–92 |
| Previous AIN | 39 (41%) | 3 (9%) | 3 (6%) | P < 0.001 |
| Previous GIN | 1 (1%) | 3 (10%) | 5 (10%) | P = 0.011 |
| Stage 1 | 40 (42%) | 11 (34%) | 11 (23%) | P = 0.071 |
| Stage 2A | 13 (14%) | 5 (16%) | 9 (19%) |
| Stage 2B | 4 (4%) | 1 (3%) | 0 (0%) |
| Stage 3A | 7 (7%) | 1 (3%) | 4 (8%) |
| Stage 3B | 11 (12%) | 1 (3%) | 3(6%) |
| Stage 3C | 16 (17%) | 6 (19%) | 10 (21%) |
| Stage 4 | 3 (17%) | 4 (13%) | 3 (6%) |
**Intraepithelial Neoplasia and other predisposing skin conditions**

Three patients had predisposing anal skin conditions linked to ASCC such as lichen sclerosis and only 3% of patients had a pre-disposing co-morbidity leading to immunosuppression other than HIV status.

Four patients had concurrent cervical and or vulval intraepithelial neoplasia and three patients had a prior treated vulval squamous cell carcinoma. One patient with high-grade cervical intraepithelial neoplasia was also HIV positive. 26% were previously diagnosed with AIN and had received follow up and/or treatment before ASCC diagnosis.

Having a previous known diagnosis of AIN before ASCC diagnosis was associated with being HIV positive (p < 0.001, Fisher's Exact Test), but there was not a similar effect with patients diagnosed with other non-anal genitourinary intraepithelial neoplasia. Being known to have AIN was associated with PLWH presenting with a stage 1 cancer when compared to PLWH without a previous AIN diagnosis (p < 0.001, Fisher's Exact Test). As a result, they were also more likely to have local excision as treatment (p < 0.001, Fisher's Exact Test) and less likely to have chemoradiotherapy.

| Treatment Received                  | HIV positive (n = 96) | HIV Negative (n = 32) | p-value |
|-------------------------------------|-----------------------|-----------------------|---------|
| Chemoradiotherapy                   | 63 (66%)              | 19 (59%)              | p = 0.009 |
| Palliative Radiotherapy only        | 1 (1%)                | 3 (9%)                | p < 0.000 |
| Local Excision of Tumour            | 30 (31%)              | 19 (59%)              | p = 0.07  |
| Abdominoperineal Resection          | 2 (2%)                | 3 (9%)                | p = 0.140  |
| Defunctioning Stoma                | 16 (17%)              | 4 (13%)               | p = 0.419  |
| Local Excision of Tumour only       | 24 (25%)              | 6 (19%)               | p = 0.016  |

**TMN Staging and Treatment of ASCC**

50% of patients presented with early-stage disease (Stage 1 35%; Stage 2A 15%) and 5% of patients presented with metastatic disease.

42% had their tumour locally excised, 61% had Chemoradiotherapy and 4% had Radiotherapy alone. 14% had a defunctioning colostomy for symptomatic control and 5% eventually underwent an abdominoperineal excision for recurrent disease. PLWH were more likely to receive chemoradiotherapy (p = 0.009, Fisher's Exact Test) and less likely to have palliative radiotherapy alone (p < 0.001, Fisher's Exact Test) (Table 4).
Clinical Outcomes

Recurrence

19% (n = 33) of patients developed a recurrence; 30 patients after completing chemoradiotherapy. 7 patients underwent an Abdominoperineal Resection as salvage surgery after their recurrence, no immediate post-operative complications were identified. There was no statistical association between recurrence rate and age, sex, hepatitis status, previous AIN treatment or previous cervical or vulval dysplasia. PLWH were more likely to develop a recurrence compared to HIV negative and non-tested patients (Table 5). However, PLWH also took longer to develop recurrent disease when compared to HIV negative patients (46.1 months compared to 17.5 months) but this was not statistically significant; (p = 0.077, ANOVA) (Fig. 2). Interestingly, as they are demographically very similar (see Table 3) if we group untested and HIV negative patients together this statistic becomes significant (46.1 months vs. 18.1 months; p = 0.022, ANOVA).

PLWH that recurred were more likely to have received chemoradiotherapy (p = 0.031, Fisher’s Exact Test) and have a moderately or poorly differentiated malignancy (Table 6).

Table 5
Recurrence and disease-free survival in HIV positive and HIV negative patients

| End Outcomes                  | HIV positive (n = 96) | HIV Negative (n = 32) | p-value |
|-------------------------------|-----------------------|-----------------------|---------|
| Recurrence                    | 22 (23%)              | 4 (13%)               | P < 0.001 |
| 5-Year Disease Free Survival  | 49 (51%)              | 9 (28%)               | p = 0.181 |
Table 6
Recurrence Variable analysis

| HIV status          | HIV positive | HIV negative | p-value |
|---------------------|--------------|--------------|---------|
|                     | Recurrence   | No Recurrence| Recurrence| No Recurrence|
|                     | (N = 22)     | (N = 74)     | (N = 4)  | (N = 28)     | (Fishers Exact Test) |
| Demographics        |              |              |          |              |                      |
| Gender              | Male 19 (86%)| Male 73 (99%)| 2 (50%)  | 11 (39%)     | P = 0.037            |
|                     | Female 3 (14%)| Female 1 (1%)| 2 (50%)  | 17 (61%)     |                      |
| Previous AIN        | 8 (36%)      | 31 (42%)     | 1 (25%)  | 2 (7%)       | P = 0.780            |
| Previous GIN        | 1 (5%)       | 0 (0%)       | 0 (0%)   | 3 (11%)      | P = 0.229            |
| Previous AIDs criteria | 9 (41%)    | 27 (37%)     | n/a      | n/a          | P = 0.763            |
| Hepatitis status    | 9 (41%)      | 23 (31%)     | 0 (0%)   | 2 (7%)       | P = 0.775            |
| HBV                 | 5 (23%)      | 14 (19%)     | 0 (0%)   | 2 (7%)       | P = 0.927            |
| HCV                 | 3 (14%)      | 6 (8%)       | 0 (0%)   | 1 (4%)       | P = 0.927            |
| HBV and HCV         |              |              |          |              |                      |
| Staging             | 7 (32%)      | 33 (45%)     | 1 (25%)  | 10 (36%)     | P = 0.443            |
| 1                   | 3 (14%)      | 10 (14%)     | 2 (50%)  | 3 (11%)      | P = 0.433            |
| 2A                  | 4 (18%)      | 4 (5%)       | 0 (0%)   | 1 (4%)       | P = 0.750            |
| 2B                  | 2 (9%)       | 5 (7%)       | 0 (0%)   | 1 (4%)       | P = 0.750            |
| 3A                  | 3 (14%)      | 8 (11%)      | 0 (0%)   | 1 (4%)       | P = 0.067            |
| 3B                  | 7 (32%)      | 9 (12%)      | 0 (0%)   | 6 (21%)      | P = 0.600            |
| 3C                  | 0 (0%)       | 3 (4%)       | 0 (0%)   | 4 (14%)      |                      |
| 4                   | 0 (0%)       | 2 (3%)       | 1 (25%)  | 2 (7%)       |                      |
| Not staged          |              |              |          |              |                      |
| Chemoradiotherapy   | 19 (89%)     | 44 (60%)     | 3 (75%)  | 16 (57%)     | P = 0.031            |
| Local excision of tumour | 4 (18%) | 26 (35%) | 2 (50%) | 17 (60%) | P = 0.104 |
| HIV status     | HIV positive | HIV negative | p-value |
|---------------|-------------|--------------|---------|
| Tumour        |             |              |         |
| differentiation| 1 (5%)      | 7 (10%)      | P = 1.000 |
|               | 2 (9%)      | 9 (12%)      | P = 1.000 |
| Foci of SCC   |             |              |         |
| Well differentiated | 12 (55%)  | 29 (39%)    | P = 0.028 |
| Moderately    |             |              |         |
| differentiated | 3 (14%)     | 7 (10%)      | P = 0.286 |
| Poorly        |             |              |         |
| differentiated | 0 (0)       | 0 (0)        |         |

**Disease Free Survival**

23% of patients died of ASCC during routine 5-year follow-up. Overall, 42% of patients achieved 5-year disease free survival and 9% were lost to follow up. 26% were diagnosed within the last 5 years and therefore could not be included in the survival analysis.

Survival was associated with < 5 cm tumour size (p < 0.000, Chi Squared) and the absence of nodal or metastatic disease at presentation (p < 0.000, Chi Squared). 70% of patients achieving 5-year Disease Free Survival were T1/2 compared to only 27% of patients with T3/T4 tumours. No patients with distant metastatic disease on presentation achieved 5-year Disease Free survival.

There was no statistical association between disease free survival and HIV status, gender, and previous AIN or non-anal intraepithelial dysplasias and malignancies.

50% of patients who were given a stoma for symptomatic control were eventually reversed. 33% patients died with a stoma in situ.

**Discussion**

ASCC is a cancer of increasing incidence in the western world,[2] which may in part be due to the increasing prevalence of HIV. This cohort study was undertaken to examine patients with ASCC at a specialist HIV referral centre with emphasis on whether PLWH have different clinical outcomes to their HIV negative counterparts.

Within this cohort, we identified a clinical subgroup of younger male PLWH who were more likely to have a previous diagnosis of AIN. The cohort also showed a difference in recurrence rates and HIV status, although HIV negative patients on average recurred earlier than PLWH there was no difference in mortality. Taking this into consideration, it is possible that as PLWH are statistically younger at the time of ASCC diagnosis, that PLWH with good viral control have a longer expected life span when compared to older HIV negative patients and are therefore they more likely to develop a recurrence in later life. Our data suggests that long term follow up, beyond the routine 5 years after ASCC treatment, may be advisable for
some PLWH as they are more likely to recur later than patients without a positive HIV test (p = 0.022, ANOVA).

The use of High Resolution Anoscopy (HRA) as a screening tool remains controversial. In recent clinical guidelines, The Association of Coloproctology in Great Britain and Ireland could not recommend screening practices such as HRA for routine clinical practice.[7] Similarly, the American Society of Colon and Rectal Surgeons limited its recommendations for the use of HRA to experienced practitioners performing screening on high risk individuals only.[6] These recommendations are based on a lack of evidence that HRA is a screening method that prevents cancer. A recent systematic review also did not identify any evidence based treatments that could definitely prevent the onset of ASCC if high-grade AIN were detected.[12] As yet there are very few studies with long enough follow up times to be able to identify a risk reduction.

Interestingly, PLWH within our cohort who also had a prior diagnosis of AIN were more likely to present with early-stage tumours (< 5 cm). We believe that this could be an important finding as the earlier detection of disease is an important criterion for a successful screening programme. Due to the retrospective nature of this cohort study, we cannot be certain however whether this finding is a result of cancer being detected earlier by HRA or whether a selection bias exists as patients who comply with a voluntary screening programme are more likely to be informed about the risks of ASCC and present earlier. There was no associated survival benefit identified but this is unsurprising as unfortunately the size of the cohort is underpowered to do so. Nevertheless, there is likely to be a significant benefit to quality of life as patients with smaller tumours are less likely to recur or require permanent colostomy. Only larger datasets involving PLWH screening programmes will be able to identify any benefits with certainty.

Recently, there have been encouraging developments in establishing datasets evaluating AIN management and ASCC prevention. The Multinational Anal Squamous Cell Carcinoma: Audit and Registry (mASCARA) started recruiting patients in 2019,[3] and pursues a collaborative approach combining sexual health, gynaecology, HIV and oncology outcomes. The dataset is being used to investigate the screening, prevention, and early diagnosis of ASCC. Moreover, the Anal Cancer HSIL Outcomes Research (ANCHOR) study (NCT02135419) is a multicentre randomised controlled trial based in the USA, which aims to determine whether the treatment of AIN does prevent ASCC. The use of datasets could improve patient outcomes and open the era of adaptive therapy for cancer patients, ideally suiting multicentric registries and international collaboratives.[3, 16, 17]

**Strengths and Limitations of study**

This is a large cohort of patients with a rare cancer, in a specialist centre for the management of HIV and ASCC. The data available permitted the review of a 20-year experience of treating ASCC in a demographic where HIV is highly prevalent. There is little previous data comparing the outcomes between HIV positive and HIV negative patient groups.
Notwithstanding the large cohort for a rare cancer; we are limited by recall bias and a high number of patients being lost to follow up. The data collection for PLWH was also more detailed in the first few years of the cohort when compared to HIV negative patients.

Interestingly, our experience did not identify any relationship between Hepatitis B and C infections that have been shown to be a risk of ASCC in other studies.\cite{18,19} and unfortunately the data available did not permit an analysis based on previous anal warts, sexual history and sexually transmitted diseases in PLWH. McCloskey et al (2017) identifies a strong increased risk of AIN with syphilis, genital herpes simplex virus and gonorrhoea infections as well as with increasing numbers of sexual partners\cite{20} it is possible that this is a hidden confounding factor.

In the past, ASCC has been associated with a higher incidence in women aged 60–70. More recently, clinical centres in England with high prevalence of HIV, such as Greater London, anecdotally have observed an increased frequency of younger male PLWH presenting with ASCC; this is demonstrated in the most recent ASCC incidence figures in England between 2013–2017. In England as a whole, there has been a 23% rise in incidence during this time period, with women having both a higher rate of incidence and larger increase in incidence rate. In contrast, in Greater London, although men still have a lower incidence rate as a whole than woman (1.41 cases per 100000 people compared to 1.74 case per 100000 people), men had a 50% increase in their incidence rate compared to only 5.5% in women in Greater London between 2013 and 2017 \cite{21}.

We anticipated that our clinical centre would have high numbers of male PLWH patients compared to the national average, but we were surprised that we had very low numbers of female patients with previous Genitourinary Intraepithelial Neoplasia (GIN) developing ASCC. This is unexpected, considering that the majority of patients with ASCC in England are female and it is likely that there is a significant cross over between HPV related dysplasia. There is a screening programme available for women with previous HPV related gynaecological dysplasia and this could be a sign that the programme is successful at our clinical centre, or it is possible that we have low rates of GIN in our region. If it is the latter, our results may not be generalisable to regions that have high volumes of patients with GIN.

A high number of our patients did not have a HIV test on clinical record. They were more likely to be female and have a previous diagnosis of Genitourinary Intraepithelial Neoplasia. It is possible that some of these patients may have had a negative HIV test elsewhere so a HIV test on diagnosis was not performed. It is very unlikely, that if patients tested positive for HIV elsewhere, for this diagnosis to be unknown to us. The untested patient subgroup was most statistically similar to the HIV negative patient subgroup (Fig. 3).

**Conclusion**

We present a 20-year experience with ASCC in a HIV tertiary referral centre. We identified a patient subset of younger male PLWH developing ASCC. Patients known to have a previous diagnosis of AIN were more likely to have earlier disease but there was not any identifiable survival benefit.
There was no statistical difference in staging and disease-free survival and HIV status. However, PLWH were more likely to recur and when this occurred, it took longer to develop recurrent disease.

Five-year Disease-Free Survival was associated with tumour size and the absence of nodal or metastatic disease.

**Declarations**

**Conflicts of Interest**

None to declare

**DATA AVAILABILITY**

The complete datasets generated and analysed in this study are not publicly available without ethical approval as they contain personally identifiable data from hospital databases. Anonymised supplementary information can be requested from the corresponding author if the request is reasonable and meets the conditions of the ethical approval granted to undertake this study.

**ETHICAL APPROVAL**

The authors confirm that the study has been approved by the London-Westminster Research and Ethics Committee and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**CODE AVAILABILITY**

Not applicable

**AUTHORS CONTRIBUTIONS**

All listed authors confirm that they had made substantial contribution to either the conception, design, acquisition, analysis, and interpretation of the data and either drafted the original article or provided critical revisions or prior drafts. All listed authors agree to the version that is published and are accountable for its accuracy and integrity.

**ACKNOWLEDGEMENTS AND FUNDING**
We thank the following for financially supporting this work: the Thornton Foundation and the Royal Marsden Cancer Charity (funding to IYC). This work represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

References

1. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. The Lancet Oncology 14 (6):516-524. doi:10.1016/s1470-2045(13)70086-x

2. Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A (2017) International trends in anal cancer incidence rates. Int J Epidemiol 46 (3):924-938. doi:https://dx.doi.org/10.1093/ije/dyw276

3. Brogden DRL, Kontovounisios C, Pellino G, Bower M, Mills SC, Tekkis PP (2019) Improving outcomes for the treatment of Anal Squamous Cell Carcinoma and Anal Intraepithelial Neoplasia. Techniques in Coloproctology 23 (12):1109-1111. doi:10.1007/s10151-019-02121-8

4. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, Grulich AE (2009) Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 23 (16):2183-2190. doi:10.1097/QAD.0b013e328331d384

5. Trickey A, May MT, Vehreschild J-J, Obel N, Gill MJ, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte AdA, van Sighem A, Saag M, Lampe F, Hernandez V, Montero M, Zangerle R, Justice AC, Sterling T, Ingle SM, Sterne JAC (2017) Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 4 (8):e349-e356. doi:10.1016/S2352-3018(17)30066-8

6. Stewart DB, Gaertner WB, Glasgow SC, Herzig DO, Feingold D, Steele SR, Prepared on Behalf of the Clinical Practice Guidelines Committee of the American Society of C, Rectal S (2018) The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018). Dis Colon Rectum 61 (7):755-774. doi:10.1097/DCR.0000000000001114

7. Geh I, Gollins S, Renehan A, Scholefield J, Goh V, Prezzi D, Moran B, Bower M, Alfa-Wali M, Adams R (2017) Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. Colorectal Dis 19 Suppl 1:82-97. doi:10.1111/codi.13709

8. Tong WWY, Jin F, McHugh LC, Maher T, Sinclair B, Grulich AE, Hillman RJ, Carr A (2013) Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS 27 (14):2233-2243. doi:10.1097/QAD.0b013e3283633111
9. Fuchs W, Wieland U, Skaletz-Rorowski A, Brockmeyer NH, Swoboda J, Kreuter A, Michalik C, Potthoff A, Competence Network for HA (2016) The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol 30 (6):995-1001. doi:https://dx.doi.org/10.1111/jdv.13539

10. Lee G, Kunitake H, Stafford C, Bordeianou L, Francone TD, Ricciardi R (2018) What is the risk of anal carcinoma in patients with anal intraepithelial neoplasia? Diseases of the Colon and Rectum 61 (5):e69-e70. doi:http://dx.doi.org/10.1097/DCR.0000000000001104

11. Scholefield JH, Harris D, Radcliffe A (2011) Guidelines for management of anal intraepithelial neoplasia. Colorectal Disease 13 Suppl 1:3-10. doi:https://dx.doi.org/10.1111/j.1463-1318.2010.02494.x

12. Brogden DRL, Walsh U, Pellino G, Kontovounisios C, Tekkis P, Mills SC (2020) Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review. Int J Colorectal Dis. doi:10.1007/s00384-020-03740-6

13. Wilkinson JR, Morris EJ, Downing A, Finan PJ, Aravani A, Thomas JD, Sebag-Montefiore D (2014) The rising incidence of anal cancer in England 1990-2010: a population-based study. Colorectal Dis 16 (7):0234-239. doi:10.1111/codi.12553

14. Shiels MS, Kreimer AR, Coughill AE, Darragh TM, Devesa SS (2015) Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior. Cancer Epidemiol Biomarkers Prev 24 (10):1548-1556. doi:10.1158/1055-9965.EPI-15-0044

15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, for the SI (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLOS Medicine 4 (10):e296. doi:10.1371/journal.pmed.0040296

16. Amelio I, Bertolo R, Bove P, Candi E, Chiocchi M, Cipriani C, Di Daniele N, Ganini C, Juhl H, Mauriello A, Marani C, Marshall J, Montanaro M, Palmieri G, Piacentini M, Sica G, Tesauro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G (2020) Cancer predictive studies. Biol Direct 15 (1):18. doi:10.1186/s13062-020-00274-3

17. EuroSurg: a new European student-driven research network in surgery (2016). Colorectal Dis 18 (2):214-215. doi:10.1111/codi.13260

18. Burgos J, Curran A, Landolfi S, Guelar A, Miguel L, Dinares M, Villar J, Navarro J, Hernandez-Losa J, Falco V (2017) Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. AIDS 31 (9):1245-1252. doi:https://dx.doi.org/10.1097/QAD.0000000000001433

19. Aldersley J, Lorenz DR, Misra V, Uno H, Gabuzda D (2019) Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. Aids 33 (1):145-152. doi:10.1097/qad.0000000000002059

20. McCloskey JC, Kast WM, Flexman JP, McCallum D, French MA, Phillips M (2017) Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res 4:90-98. doi:10.1016/j.pvr.2017.10.004
Figures

Figure 1

STROBE Flow Chart Flow chart describing method of identification of patients included in cohort and reasons for exclusion.
Figure 2

The relationship between HIV status and recurrence time. Log rank Kaplan Meier Curve demonstrating time from primary ASCC diagnosis to development of local or distant recurrent disease stratified by HIV test status.